Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells $33,592.14 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,586 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $33,592.14. Following the sale, the insider now owns 44,746 shares in the company, valued at $581,250.54. This represents a 5.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Friday, December 6th, Barry Ticho sold 13,945 shares of Stoke Therapeutics stock. The shares were sold at an average price of $12.78, for a total value of $178,217.10.
• On Monday, December 2nd, Barry Ticho sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.07, for a total value of $120,700.00.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded down $0.28 during trading hours on Wednesday, hitting $12.98. The stock had a trading volume of 283,002 shares, compared to its average volume of 748,105. The stock’s fifty day simple moving average is $12.46 and its 200 day simple moving average is $13.68. The firm has a market capitalization of $687.55 million, a price-to-earnings ratio of -6.15 and a beta of 0.95. Stoke Therapeutics, Inc. has a 1-year low of $4.09 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Analyst Ratings Changes

STOK has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partners started coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $20.83.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Barclays PLC grew its position in Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after buying an additional 47,239 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after acquiring an additional 76,661 shares during the period. Jane Street Group LLC boosted its holdings in shares of Stoke Therapeutics by 338.2% in the third quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after acquiring an additional 255,028 shares in the last quarter. State Street Corp increased its stake in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares during the period. Finally, RTW Investments LP raised its holdings in Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.